Biontech Se Stock Number Of Shares Shorted

BNTX Stock

USD 118.39 2.33 1.93%

BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioNTech SE Company Number Of Shares Shorted Analysis

BioNTech's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Shares Shorted

Shorted by Public

+

by Institutions

More About Number Of Shares Shorted | All Equity Analysis

Current BioNTech Number Of Shares Shorted

2.47 M

Most of BioNTech's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BioNTech Number Of Shares Shorted Driver Correlations

Understanding the fundamental principles of building solid financial models for BioNTech is extremely important. It helps to project a fair market value of BioNTech Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since BioNTech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioNTech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioNTech's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Long Term Investments	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	0.62	-0.93	0.99	0.94	0.68	0.82	0.76	0.86	0.75	1.0	0.67	0.81	0.67	1.0	1.0	0.86
Total Stockholder Equity	1.0		0.62	-0.95	1.0	0.95	0.64	0.83	0.78	0.84	0.78	0.99	0.63	0.83	0.66	1.0	1.0	0.85
Current Deferred Revenue	0.62	0.62		-0.53	0.6	0.8	0.26	0.79	0.74	0.49	0.72	0.59	0.46	0.78	0.72	0.62	0.6	0.85
Net Debt	-0.93	-0.95	-0.53		-0.95	-0.88	-0.43	-0.78	-0.72	-0.69	-0.74	-0.92	-0.37	-0.78	-0.58	-0.94	-0.94	-0.78
Retained Earnings	0.99	1.0	0.6	-0.95		0.95	0.6	0.85	0.8	0.81	0.8	0.99	0.59	0.84	0.62	1.0	0.99	0.83
Accounts Payable	0.94	0.95	0.8	-0.88	0.95		0.49	0.94	0.9	0.73	0.89	0.92	0.59	0.94	0.71	0.95	0.93	0.89
Net Receivables	0.68	0.64	0.26	-0.43	0.6	0.49		0.24	0.16	0.92	0.14	0.72	0.92	0.24	0.51	0.64	0.68	0.54
Good Will	0.82	0.83	0.79	-0.78	0.85	0.94	0.24		0.99	0.51	0.99	0.78	0.41	0.99	0.54	0.83	0.8	0.8
Short Term Investments	0.76	0.78	0.74	-0.72	0.8	0.9	0.16	0.99		0.43	1.0	0.71	0.35	0.99	0.46	0.77	0.74	0.73
Total Liab	0.86	0.84	0.49	-0.69	0.81	0.73	0.92	0.51	0.43		0.41	0.89	0.9	0.51	0.67	0.84	0.86	0.77
Long Term Investments	0.75	0.78	0.72	-0.74	0.8	0.89	0.14	0.99	1.0	0.41		0.71	0.31	0.99	0.45	0.77	0.74	0.71
Total Current Assets	1.0	0.99	0.59	-0.92	0.99	0.92	0.72	0.78	0.71	0.89	0.71		0.69	0.77	0.66	0.99	1.0	0.84
Short Term Debt	0.67	0.63	0.46	-0.37	0.59	0.59	0.92	0.41	0.35	0.9	0.31	0.69		0.41	0.6	0.63	0.65	0.64
Intangible Assets	0.81	0.83	0.78	-0.78	0.84	0.94	0.24	0.99	0.99	0.51	0.99	0.77	0.41		0.59	0.83	0.8	0.8
Common Stock	0.67	0.66	0.72	-0.58	0.62	0.71	0.51	0.54	0.46	0.67	0.45	0.66	0.6	0.59		0.66	0.66	0.84
Net Invested Capital	1.0	1.0	0.62	-0.94	1.0	0.95	0.64	0.83	0.77	0.84	0.77	0.99	0.63	0.83	0.66		1.0	0.86
Net Working Capital	1.0	1.0	0.6	-0.94	0.99	0.93	0.68	0.8	0.74	0.86	0.74	1.0	0.65	0.8	0.66	1.0		0.85
Capital Stock	0.86	0.85	0.85	-0.78	0.83	0.89	0.54	0.8	0.73	0.77	0.71	0.84	0.64	0.8	0.84	0.86	0.85

Click cells to compare fundamentals

If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Competition

Predict BioNTech

Based on the recorded statements, BioNTech SE has 2.47 M of outstending shares currently sold short by investors. This is 22.74% lower than that of the Biotechnology sector and 51.51% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 47.47% higher than that of the company.

BioNTech Number Of Shares Shorted Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.

BioNTech is currently under evaluation in number of shares shorted category among its peers.

BioNTech Current Valuation Drivers

We derive many important indicators used in calculating different scores of BioNTech from analyzing BioNTech's financial statements. These drivers represent accounts that assess BioNTech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioNTech's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	2.8B	6.4B	15.7B	34.1B	23.2B	24.4B
Enterprise Value	2.5B	5.9B	14.7B	20.5B	11.7B	7.7B

BioNTech ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioNTech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioNTech's managers, analysts, and investors.

Environmental

Governance

Social

BioNTech Fundamentals

	Return On Equity	-0.024
	Return On Asset	-0.0124
	Profit Margin	(0.15) %
	Operating Margin	0.02 %
	Current Valuation	10.99 B
	Shares Outstanding	239.74 M
	Shares Owned By Insiders	61.65 %
	Shares Owned By Institutions	20.64 %
	Number Of Shares Shorted	2.47 M
	Price To Earning	5.19 X
	Price To Book	1.41 X
	Price To Sales	9.52 X
	Revenue	3.82 B
	Gross Profit	16.07 B
	EBITDA	1.09 B
	Net Income	1.19 B
	Cash And Equivalents	9.33 B
	Cash Per Share	38.30 X
	Total Debt	219.1 M
	Debt To Equity	0.01 %
	Current Ratio	5.15 X
	Book Value Per Share	79.73 X
	Cash Flow From Operations	5.37 B
	Short Ratio	2.64 X
	Earnings Per Share	(2.05) X
	Price To Earnings To Growth	0.04 X
	Target Price	129.5
	Number Of Employees	6.13 K
	Beta	0.26
	Market Capitalization	28.94 B
	Total Asset	23.01 B
	Retained Earnings	19.76 B
	Working Capital	17.46 B
	Current Asset	284.67 M
	Current Liabilities	143.37 M
	Net Asset	23.01 B

About BioNTech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC